Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
$2.39
+0.2%
$2.24
$1.11
$17.88
$46.48M1.57507,141 shs191,018 shs
Ampliphi Biosciences Corp stock logo
APHB
Ampliphi Biosciences
$2.17
+11.9%
$1.72
$0.15
$1.37
$72.63MN/A842,200 shs43,768 shs
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
$1.69
+3.4%
$1.86
$0.89
$3.19
$50.62M0.12295,893 shs244,351 shs
Medicure Inc. stock logo
MPH
Medicure
C$1.25
-1.6%
C$1.04
C$0.63
C$1.27
C$13.05M0.94,035 shs1,500 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
0.00%+13.79%-25.42%+93.12%-78.51%
Ampliphi Biosciences Corp stock logo
APHB
Ampliphi Biosciences
0.00%+8.50%+11.86%+69.53%-18.73%
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
0.00%-14.21%-11.98%+2.42%+40.83%
Medicure Inc. stock logo
MPH
Medicure
0.00%0.00%+6.84%+92.31%+6.84%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
1.4995 of 5 stars
3.51.00.00.00.01.70.6
Ampliphi Biosciences Corp stock logo
APHB
Ampliphi Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
3.0303 of 5 stars
3.65.00.00.02.60.00.6
Medicure Inc. stock logo
MPH
Medicure
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
3.00
Buy$18.00654.72% Upside
Ampliphi Biosciences Corp stock logo
APHB
Ampliphi Biosciences
0.00
N/AN/AN/A
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
3.17
Buy$8.20385.21% Upside
Medicure Inc. stock logo
MPH
Medicure
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ANVS, GANX, MPH, TILS, and APHB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/9/2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $12.00
5/19/2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
5/15/2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$26.00 ➝ $17.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/A$0.67 per shareN/A
Ampliphi Biosciences Corp stock logo
APHB
Ampliphi Biosciences
N/AN/AN/AN/AN/AN/A
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
$50K1,012.31N/AN/A$0.28 per share6.04
Medicure Inc. stock logo
MPH
Medicure
C$21.08M0.62C$0.50 per share2.49C$1.91 per share0.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$24.59M-$2.16N/AN/AN/AN/A-300.56%-193.50%8/13/2025 (Estimated)
Ampliphi Biosciences Corp stock logo
APHB
Ampliphi Biosciences
N/AN/A0.00N/AN/AN/AN/AN/A
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$20.41M-$0.86N/AN/AN/AN/A-247.55%-146.06%8/6/2025 (Estimated)
Medicure Inc. stock logo
MPH
Medicure
-C$2.03M-C$0.19N/AN/A-9.65%-10.18%-5.63%N/A

Latest ANVS, GANX, MPH, TILS, and APHB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
-$0.16-$0.16N/A-$0.16$0.03 millionN/A
5/13/2025Q1 2025
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
-$0.47-$0.32+$0.15-$0.32N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/AN/AN/AN/AN/A
Ampliphi Biosciences Corp stock logo
APHB
Ampliphi Biosciences
N/AN/AN/AN/AN/A
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
N/AN/AN/AN/AN/A
Medicure Inc. stock logo
MPH
Medicure
N/A2.24%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
N/A
10.68
10.68
Ampliphi Biosciences Corp stock logo
APHB
Ampliphi Biosciences
N/AN/AN/A
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
0.05
2.22
2.22
Medicure Inc. stock logo
MPH
Medicure
4.65
2.03
1.29

Institutional Ownership

CompanyInstitutional Ownership
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
15.83%
Ampliphi Biosciences Corp stock logo
APHB
Ampliphi Biosciences
N/A
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
11.97%
Medicure Inc. stock logo
MPH
Medicure
23.10%

Insider Ownership

CompanyInsider Ownership
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
20.80%
Ampliphi Biosciences Corp stock logo
APHB
Ampliphi Biosciences
N/A
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
7.18%
Medicure Inc. stock logo
MPH
Medicure
26.68%
CompanyEmployeesShares OutstandingFree FloatOptionable
Annovis Bio, Inc. stock logo
ANVS
Annovis Bio
319.49 million15.43 millionOptionable
Ampliphi Biosciences Corp stock logo
APHB
Ampliphi Biosciences
3033.47 millionN/ANot Optionable
Gain Therapeutics, Inc. stock logo
GANX
Gain Therapeutics
2029.95 million27.80 millionOptionable
Medicure Inc. stock logo
MPH
Medicure
N/A10.44 millionN/ANot Optionable

Recent News About These Companies

Medicure Inc. (NGQ1.F)
Medicure Inc. (MPH.V)
MPH:CA Medicure Inc.
Fastest Cars In The World Ranked

New MarketBeat Followers Over Time

Media Sentiment Over Time

Annovis Bio stock logo

Annovis Bio NYSE:ANVS

$2.38 +0.01 (+0.21%)
Closing price 07/3/2025 03:50 PM Eastern
Extended Trading
$2.36 -0.02 (-1.05%)
As of 08:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Ampliphi Biosciences stock logo

Ampliphi Biosciences NYSEAMERICAN:APHB

$2.17 +0.23 (+11.86%)
As of 07/3/2025

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.

Gain Therapeutics stock logo

Gain Therapeutics NASDAQ:GANX

$1.69 +0.06 (+3.36%)
Closing price 07/3/2025 03:32 PM Eastern
Extended Trading
$1.76 +0.08 (+4.44%)
As of 08:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Medicure stock logo

Medicure CVE:MPH

C$1.25 -0.02 (-1.57%)
As of 06/27/2025

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.